Document is current
Any future updates will be listed below
-
Authors
Lutzky, Jose https://orcid.org/0000-0002-9503-2130
Sullivan, Ryan J.
Cohen, Justine V.
Ren, Yixin
Li, Anlong
Haq, Rizwan
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03408587 at ClinicalTrials.govDocuments that mention this clinical trial
Phase 1b study of intravenous coxsackievirus A21 (V937) and ipilimumab for patients with metastatic uveal melanoma
https://doi.org/10.1007/s00432-022-04510-3
-
Funding
Funding for this research was provided by:
This study was funded by Viralytics Limited, a wholly owned subsidiary of Merck & Co., Inc., Rahway, NJ, USA.
- License Information
-
More Information
Article History
Received: 17 October 2022
Accepted: 30 November 2022
First Online: 18 January 2023
Declarations
:
: Jose Lutzky has served on advisory boards and/or has been a consultant for Eisai, BMS, Iovance, and Replimune, and has received research grant support from BMS. Ryan J. Sullivan has served on advisory boards and/or has been a consultant for BMS, Eisai, Iovance, Merck, Novartis, OncoSec, and Pfizer, and has received research grant support from Merck. Justine V. Cohen has served on advisory boards for Regeneron and Sanofi-Genzyme. Yixin Ren and Anlong Li are employees of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA and stockholders in Merck & Co., Inc., Rahway, NJ, USA. Rizwan Haq is a consultant for Tango Therapeutics and has received research grant support from BMS and Novartis.
: All patients provided written informed consent to participate. The study was conducted in accordance with the Declaration of Helsinki, the International Council for Harmonisation Good Clinical Practice guidelines, and all applicable local and national laws. The institutional review board at each study site approved the protocol, all protocol amendments, and informed consent forms before the study began.
: Not applicable.
